NervGen Pharma (TSXV:NGEN) Institutional Ownership: 0.00% (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NGEN NervGen Pharma Corp TSXV:NGEN
14 GF Score
Price C$5.15
! 2 Warning Signs
View Full Analysis

What is NervGen Pharma Institutional Ownership?

NervGen Pharma TSXV:NGEN 14 Institutional Ownership is 0.00% as of Aug. 23, 2026. GuruFocus rates TSXV:NGEN with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NervGen Pharma's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NervGen Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NervGen Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.

NervGen Pharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for NervGen Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma Institutional Ownership Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Institutional Ownership
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

NervGen Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Institutional Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:NGEN
14GF Score
NervGen Pharma Corp TSXV:NGEN
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NervGen Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.00% mean?
NervGen Pharma (TSXV:NGEN) has a Institutional Ownership of 0.00% as of Aug. 23, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on NervGen Pharma and its competitors.
Is NervGen Pharma's Institutional Ownership too high?
NervGen Pharma's current Institutional Ownership is 0.00%. Overall, NervGen Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's Institutional Ownership compare to LENZ and ARMP?
NervGen Pharma's Institutional Ownership of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on NervGen Pharma and its competitors. NervGen Pharma's current Institutional Ownership is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (TSXV:NGEN) has a current Institutional Ownership of 0.00%. The current Institutional Ownership is 0.00%. NervGen Pharma's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For NervGen Pharma (TSXV:NGEN), the current Institutional Ownership is 0.00% as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NervGen Pharma Business Description

Other Exchanges NGEN:USA9UA:Germany
Address 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
14GF Score

Get the complete analysis for TSXV:NGEN

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$5.15
Price